Skip to content

Study · Animal study (in vivo) · mouse · 2018

8 results

Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.

Bitto A, Irrera N, Pizzino G, Pallio G, Mannino F, Vaccaro M, Arcoraci V, Aliquò F, Minutoli L, Colonna MR, Galeano MR, Brines M and 4 more

Show all authors

De Ponte C, Collino M, Squadrito F, Altavilla D

Biochimica et biophysica acta. Molecular basis of disease7 Dec 2017Cited by 12 (Europe PMC)

PMID29223734 (opens in a new tab)DOI10.1016/j.bbadis.2017.12.006 (opens in a new tab)PepBankPUB-29223734
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with incisional wounds, cibinetide significantly improved the increased wound malondialdehyde seen with vehicle.

    In plain wordsIn diabetic mice, cibinetide improved the raised oxidative damage marker in wounds, compared with vehicle.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseWound malondialdehyde (MAL)
    Study

    mousen: not reported in source

    Incisional wound model in genetic diabetic (db+/db+) mice
    Comparator
    Vehicle
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    30 µg/kg · subcutaneous · up to 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Throughout the wound healing process diabetic animals treated with vehicle exhibited increased wound MAL with reduced VEGF, pAkt, peNOS and nitrite/nitrate, all associated with poor re-epitheliziation, angiogenesis, and wound breaking strength. Cibenitide administration significantly improved these abnormalities.
    2 context sentences
    Summary · context
    A specific IRR agonist cibinetide was administered in an incisional wound healing model performed mice with genetic diabetes (db+/db+) and compared to the normal wild-type.
    Summary · context
    Animals were treated daily with cibinetide (30μg/kg/s.c.) or vehicle and euthanized 3, 7, and 14days after the injury to quantitate vascular endothelial growth factor (VEGF), malondialdehyde (MAL), phospho-Akt (pAkt), phospho e-NOS (p-eNOS), and nitrite/nitrate content within the wound.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with incisional wounds, cibinetide significantly improved the reduced wound VEGF seen with vehicle.

    In plain wordsIn diabetic mice, cibinetide improved the low wound VEGF levels, compared with vehicle.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseWound VEGF
    Study

    mousen: not reported in source

    Incisional wound model in genetic diabetic (db+/db+) mice
    Comparator
    Vehicle
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    30 µg/kg · subcutaneous · up to 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Throughout the wound healing process diabetic animals treated with vehicle exhibited increased wound MAL with reduced VEGF, pAkt, peNOS and nitrite/nitrate, all associated with poor re-epitheliziation, angiogenesis, and wound breaking strength. Cibenitide administration significantly improved these abnormalities.
    2 context sentences
    Summary · context
    A specific IRR agonist cibinetide was administered in an incisional wound healing model performed mice with genetic diabetes (db+/db+) and compared to the normal wild-type.
    Summary · context
    Animals were treated daily with cibinetide (30μg/kg/s.c.) or vehicle and euthanized 3, 7, and 14days after the injury to quantitate vascular endothelial growth factor (VEGF), malondialdehyde (MAL), phospho-Akt (pAkt), phospho e-NOS (p-eNOS), and nitrite/nitrate content within the wound.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with incisional wounds, cibinetide significantly improved the reduced wound pAkt seen with vehicle.

    In plain wordsIn diabetic mice, cibinetide improved the low wound pAkt levels, compared with vehicle.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseWound phospho-Akt (pAkt)
    Study

    mousen: not reported in source

    Incisional wound model in genetic diabetic (db+/db+) mice
    Comparator
    Vehicle
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    30 µg/kg · subcutaneous · up to 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Throughout the wound healing process diabetic animals treated with vehicle exhibited increased wound MAL with reduced VEGF, pAkt, peNOS and nitrite/nitrate, all associated with poor re-epitheliziation, angiogenesis, and wound breaking strength. Cibenitide administration significantly improved these abnormalities.
    2 context sentences
    Summary · context
    A specific IRR agonist cibinetide was administered in an incisional wound healing model performed mice with genetic diabetes (db+/db+) and compared to the normal wild-type.
    Summary · context
    Animals were treated daily with cibinetide (30μg/kg/s.c.) or vehicle and euthanized 3, 7, and 14days after the injury to quantitate vascular endothelial growth factor (VEGF), malondialdehyde (MAL), phospho-Akt (pAkt), phospho e-NOS (p-eNOS), and nitrite/nitrate content within the wound.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with incisional wounds, cibinetide significantly improved the reduced wound p-eNOS seen with vehicle.

    In plain wordsIn diabetic mice, cibinetide improved the low wound p-eNOS levels, compared with vehicle.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseWound phospho-eNOS (p-eNOS)
    Study

    mousen: not reported in source

    Incisional wound model in genetic diabetic (db+/db+) mice
    Comparator
    Vehicle
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    30 µg/kg · subcutaneous · up to 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Throughout the wound healing process diabetic animals treated with vehicle exhibited increased wound MAL with reduced VEGF, pAkt, peNOS and nitrite/nitrate, all associated with poor re-epitheliziation, angiogenesis, and wound breaking strength. Cibenitide administration significantly improved these abnormalities.
    2 context sentences
    Summary · context
    A specific IRR agonist cibinetide was administered in an incisional wound healing model performed mice with genetic diabetes (db+/db+) and compared to the normal wild-type.
    Summary · context
    Animals were treated daily with cibinetide (30μg/kg/s.c.) or vehicle and euthanized 3, 7, and 14days after the injury to quantitate vascular endothelial growth factor (VEGF), malondialdehyde (MAL), phospho-Akt (pAkt), phospho e-NOS (p-eNOS), and nitrite/nitrate content within the wound.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with incisional wounds, cibinetide significantly improved the reduced wound nitrite/nitrate seen with vehicle.

    In plain wordsIn diabetic mice, cibinetide improved the low wound nitrite and nitrate levels, compared with vehicle.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseWound nitrite/nitrate content
    Study

    mousen: not reported in source

    Incisional wound model in genetic diabetic (db+/db+) mice
    Comparator
    Vehicle
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    30 µg/kg · subcutaneous · up to 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Throughout the wound healing process diabetic animals treated with vehicle exhibited increased wound MAL with reduced VEGF, pAkt, peNOS and nitrite/nitrate, all associated with poor re-epitheliziation, angiogenesis, and wound breaking strength. Cibenitide administration significantly improved these abnormalities.
    2 context sentences
    Summary · context
    A specific IRR agonist cibinetide was administered in an incisional wound healing model performed mice with genetic diabetes (db+/db+) and compared to the normal wild-type.
    Summary · context
    Animals were treated daily with cibinetide (30μg/kg/s.c.) or vehicle and euthanized 3, 7, and 14days after the injury to quantitate vascular endothelial growth factor (VEGF), malondialdehyde (MAL), phospho-Akt (pAkt), phospho e-NOS (p-eNOS), and nitrite/nitrate content within the wound.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with incisional wounds, cibinetide significantly improved the poor re-epithelialization seen with vehicle.

    In plain wordsIn diabetic mice, cibinetide improved the poor skin regrowth over wounds, compared with vehicle.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseRe-epithelialization
    Study

    mousen: not reported in source

    Incisional wound model in genetic diabetic (db+/db+) mice
    Comparator
    Vehicle
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    30 µg/kg · subcutaneous · up to 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Throughout the wound healing process diabetic animals treated with vehicle exhibited increased wound MAL with reduced VEGF, pAkt, peNOS and nitrite/nitrate, all associated with poor re-epitheliziation, angiogenesis, and wound breaking strength. Cibenitide administration significantly improved these abnormalities.
    2 context sentences
    Summary · context
    A specific IRR agonist cibinetide was administered in an incisional wound healing model performed mice with genetic diabetes (db+/db+) and compared to the normal wild-type.
    Summary · context
    Animals were treated daily with cibinetide (30μg/kg/s.c.) or vehicle and euthanized 3, 7, and 14days after the injury to quantitate vascular endothelial growth factor (VEGF), malondialdehyde (MAL), phospho-Akt (pAkt), phospho e-NOS (p-eNOS), and nitrite/nitrate content within the wound.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with incisional wounds, cibinetide significantly improved the poor angiogenesis seen with vehicle.

    In plain wordsIn diabetic mice, cibinetide improved the poor growth of new blood vessels in wounds, compared with vehicle.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseWound angiogenesis
    Study

    mousen: not reported in source

    Incisional wound model in genetic diabetic (db+/db+) mice
    Comparator
    Vehicle
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    30 µg/kg · subcutaneous · up to 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Throughout the wound healing process diabetic animals treated with vehicle exhibited increased wound MAL with reduced VEGF, pAkt, peNOS and nitrite/nitrate, all associated with poor re-epitheliziation, angiogenesis, and wound breaking strength. Cibenitide administration significantly improved these abnormalities.
    2 context sentences
    Summary · context
    A specific IRR agonist cibinetide was administered in an incisional wound healing model performed mice with genetic diabetes (db+/db+) and compared to the normal wild-type.
    Summary · context
    Animals were treated daily with cibinetide (30μg/kg/s.c.) or vehicle and euthanized 3, 7, and 14days after the injury to quantitate vascular endothelial growth factor (VEGF), malondialdehyde (MAL), phospho-Akt (pAkt), phospho e-NOS (p-eNOS), and nitrite/nitrate content within the wound.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice with incisional wounds, cibinetide significantly improved the poor wound breaking strength seen with vehicle.

    In plain wordsIn diabetic mice, cibinetide improved the weak wound strength, compared with vehicle.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseWound breaking strength
    Study

    mousen: not reported in source

    Incisional wound model in genetic diabetic (db+/db+) mice
    Comparator
    Vehicle
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    30 µg/kg · subcutaneous · up to 14 daysAs given in this study (mouse).

    Source sentences

    Summary
    Throughout the wound healing process diabetic animals treated with vehicle exhibited increased wound MAL with reduced VEGF, pAkt, peNOS and nitrite/nitrate, all associated with poor re-epitheliziation, angiogenesis, and wound breaking strength. Cibenitide administration significantly improved these abnormalities.
    2 context sentences
    Summary · context
    A specific IRR agonist cibinetide was administered in an incisional wound healing model performed mice with genetic diabetes (db+/db+) and compared to the normal wild-type.
    Summary · context
    Animals were treated daily with cibinetide (30μg/kg/s.c.) or vehicle and euthanized 3, 7, and 14days after the injury to quantitate vascular endothelial growth factor (VEGF), malondialdehyde (MAL), phospho-Akt (pAkt), phospho e-NOS (p-eNOS), and nitrite/nitrate content within the wound.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.